Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 390892, 12 pages
http://dx.doi.org/10.1155/2012/390892
Review Article

Thrombopoietin as Biomarker and Mediator of Cardiovascular Damage in Critical Diseases

1Department of Clinical Pathophysiology, University of Turin, via Genova 3, 10126 Turin, Italy
2Critical Care Department, Saint Michael’s Hospital, Toronto, ON, Canada M5B 1W8

Received 5 December 2011; Accepted 1 February 2012

Academic Editor: Aldo Pende

Copyright © 2012 Enrico Lupia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Vigon, J. P. Mornon, L. Cocault et al., “Molecular cloning and characterization of MPL, the human homolog of the v- mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5640–5644, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Souyri, I. Vigon, J. F. Penciolelli, J. M. Heard, P. Tambourin, and F. Wendling, “A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors,” Cell, vol. 63, no. 6, pp. 1137–1147, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. A. L. Gurney, K. Carver-Moore, F. J. de Sauvage, and M. W. Moore, “Thrombocytopenia in c-mpl-deficient mice,” Science, vol. 265, no. 5177, pp. 1445–1447, 1994. View at Google Scholar · View at Scopus
  4. S. Lok, K. Kaushansky, R. D. Holly et al., “Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo,” Nature, vol. 369, no. 6481, pp. 565–568, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Wendling, E. Maraskovsky, N. Debili et al., “c-Mpl ligand is a humoral regulator of megakaryocytopoiesis,” Nature, vol. 369, no. 6481, pp. 571–574, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Kuter, D. L. Beeler, and R. D. Rosenberg, “The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 11104–11108, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. T. D. Bartley, J. Bogenberger, P. Hunt et al., “Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl,” Cell, vol. 77, no. 7, pp. 1117–1124, 1994. View at Google Scholar · View at Scopus
  8. F. J. De Sauvage, P. E. Hass, S. D. Spencer et al., “Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand,” Nature, vol. 369, no. 6481, pp. 533–538, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Sohma, H. Akahori, N. Seki et al., “Molecular cloning and chromosomal localization of the human thrombopoietin gene,” FEBS Letters, vol. 353, no. 1, pp. 57–61, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Kato, K. Ogami, Y. Shimada et al., “Purification and characterization of thrombopoietin,” Journal of Biochemistry, vol. 118, no. 1, pp. 229–236, 1995. View at Google Scholar · View at Scopus
  11. F. S. Chou and J. C. Mulloy, “The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis,” Journal of Cellular Biochemistry, vol. 112, no. 6, pp. 1491–1498, 2011. View at Publisher · View at Google Scholar
  12. Y. Ezumi, H. Takayama, and M. Okuma, “Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro,” FEBS Letters, vol. 374, no. 1, pp. 48–52, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kaushansky, N. Lin, A. Grossmann, J. Humes, K. H. Sprugel, and V. C. Broudy, “Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice,” Experimental Hematology, vol. 24, no. 2, pp. 265–269, 1996. View at Google Scholar · View at Scopus
  14. W. S. Alexander, A. W. Roberts, N. A. Nicola, R. Li, and D. Metcalf, “Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl,” Blood, vol. 87, no. 6, pp. 2162–2170, 1996. View at Google Scholar · View at Scopus
  15. K. Carver-Moore, H. E. Broxmeyer, S. M. Luoh et al., “Low levels of erythroid and myeloid progenitors in thrombopoietin- and c- mpl-deficient mice,” Blood, vol. 88, no. 3, pp. 803–808, 1996. View at Google Scholar · View at Scopus
  16. T. Matsunaga, T. Kato, H. Miyazaki, and M. Ogawa, “Thrombopoietin promotes the survival of murine hematopoietic long-term reconstituting cells: comparison with the effects of FLT3/FLK-2 ligand and interleukin-6,” Blood, vol. 92, no. 2, pp. 452–461, 1998. View at Google Scholar · View at Scopus
  17. M. Yagi, K. A. Ritchie, E. Sitnicka, C. Storey, G. J. Roth, and S. Bartelmez, “Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 14, pp. 8126–8131, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. R. V. B. Emmons, D. M. Reid, R. L. Cohen et al., “Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction,” Blood, vol. 87, no. 10, pp. 4068–4071, 1996. View at Google Scholar · View at Scopus
  19. S. Kosugi, Y. Kurata, Y. Tomiyama et al., “Circulating thrombopoietin level in chronic immune thrombocytopenic purpura,” British Journal of Haematology, vol. 93, no. 3, pp. 704–706, 1996. View at Google Scholar · View at Scopus
  20. A. Cerutti, P. Custodi, M. Duranti, P. Noris, and C. L. Balduini, “Thrombopoietin levels in patients with primary and reactive thrombocytosis,” British Journal of Haematology, vol. 99, no. 2, pp. 281–284, 1997. View at Google Scholar · View at Scopus
  21. P. Imbach and M. Crowther, “Thrombopoietin-receptor agonists for primary immune thrombocytopenia,” The New England Journal of Medicine, vol. 365, no. 8, pp. 734–741, 2011. View at Publisher · View at Google Scholar
  22. L. M. Aledort, C. P. M. Hayward, M. G. Chen, J. L. Nichol, and J. Bussel, “Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies,” American Journal of Hematology, vol. 76, no. 3, pp. 205–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Rhodes and R. Stasi, “Current status of thrombopoietic agents,” Expert Review of Hematology, vol. 3, no. 2, pp. 217–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Şenaran, M. Ileri, A. Altinbaş et al., “Thrombopoietin and mean platelet volume in coronary artery disease,” Clinical Cardiology, vol. 24, no. 5, pp. 405–408, 2001. View at Google Scholar
  25. E. Lupia, O. Bosco, S. Bergerone et al., “Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina,” Journal of the American College of Cardiology, vol. 48, no. 11, pp. 2195–2203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Colarizi, P. Fiorucci, A. Caradonna, F. Ficuccilli, M. Mancuso, and P. Papoff, “Circulating thrombopoietin levels in neonates with infection,” Acta Paediatrica, vol. 88, no. 3, pp. 332–337, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Jilma-Stohlawetz, C. C. Folman, A. E. G. K. Von Dem Borne et al., “Effects of anticoagulation on thrombopoietin release during endotoxemia,” Journal of Laboratory and Clinical Medicine, vol. 137, no. 1, pp. 64–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Stohlawetz, C. C. Folman, A. E. K. Von Dem Borne et al., “Effects of endotoxemia on thrombopoiesis in men,” Thrombosis and Haemostasis, vol. 81, no. 4, pp. 613–617, 1999. View at Google Scholar · View at Scopus
  29. S. G. Zakynthinos, S. Papanikolaou, T. Theodoridis et al., “Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients,” Critical Care Medicine, vol. 32, no. 4, pp. 1004–1010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Montrucchio, M. F. Brizzi, G. Calosso, S. Marengo, L. Pegoraro, and G. Camussi, “Effects of recombinant human megakaryocyte growth and development factor on platelet activation,” Blood, vol. 87, no. 7, pp. 2762–2768, 1996. View at Google Scholar · View at Scopus
  31. A. Oda, Y. Miyakawa, B. J. Druker et al., “Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists,” Blood, vol. 87, no. 11, pp. 4664–4670, 1996. View at Google Scholar · View at Scopus
  32. H. E. Tibbles, C. S. Navara, M. A. Hupke, A. O. Vassilev, and F. M. Uckun, “Thrombopoietin induces P-selectin expression on platelets and subsequent platelet/leukocyte interactions,” Biochemical and Biophysical Research Communications, vol. 292, no. 4, pp. 987–991, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Fitzgerald, L. Roy, F. Catella, and C. A. FitzGerald, “Platelet activation in unstable coronary disease,” The New England Journal of Medicine, vol. 315, no. 16, pp. 983–989, 1986. View at Google Scholar · View at Scopus
  34. K. A. Ault, C. P. Cannon, J. Mitchell et al., “Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial,” Journal of the American College of Cardiology, vol. 33, no. 3, pp. 634–639, 1999. View at Publisher · View at Google Scholar
  35. Y. Yeghiazarians, J. B. Braunstein, A. Askari, and P. H. Stone, “Unstable angina pectoris,” The New England Journal of Medicine, vol. 342, no. 2, pp. 101–114, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Y. Chakhtoura, F. E. Shamoon, J. I. Haft, G. R. Obiedzinski, A. J. Cohen, and R. M. Watson, “Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings,” American Journal of Cardiology, vol. 86, no. 8, pp. 835–839, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Y. Chirkov, A. S. Holmes, S. R. Willoughby et al., “Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets,” Journal of the American College of Cardiology, vol. 37, no. 7, pp. 1851–1857, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. J. E. Freedman and J. Loscalzo, “Platelet-monocyte aggregates: bridging thrombosis and inflammation,” Circulation, vol. 105, no. 18, pp. 2130–2132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Sarma, C. A. Laan, S. Alam, A. Jha, K. A. A. Fox, and I. Dransfield, “Increased platelet binding to circulating monocytes in acute coronary syndromes,” Circulation, vol. 105, no. 18, pp. 2166–2171, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Lange and L. D. Hillis, “Antiplatelet Therapy for Ischemic Heart Disease,” The New England Journal of Medicine, vol. 350, no. 3, pp. 277–280, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Montrucchio, O. Bosco, L. Del Sorbo et al., “Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood,” Journal of Thrombosis and Haemostasis, vol. 90, no. 5, pp. 872–881, 2003. View at Google Scholar
  42. P. J. Fielder, P. Hass, M. Nagel et al., “Human platelets as a model for the binding and degradation of thrombopoietin,” Blood, vol. 89, no. 8, pp. 2782–2788, 1997. View at Google Scholar · View at Scopus
  43. J. Li, Y. Xia, and D. J. Kuter, “Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics,” British Journal of Haematology, vol. 106, no. 2, pp. 345–356, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Nishiyama, H. Morita, Y. Torii et al., “Platelets exposed to elevated levels of endogenous thrombopoietin in vivo have a reduced response to megakaryocyte growth and development factor in vitro,” Thrombosis and Haemostasis, vol. 85, no. 1, pp. 152–159, 2001. View at Google Scholar · View at Scopus
  45. M. Ballmaier, H. Schulze, G. Strauß et al., “Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin,” Blood, vol. 90, no. 2, pp. 612–619, 1997. View at Google Scholar · View at Scopus
  46. U. Nishiyama, T. Kuwaki, H. Akahori, T. Kato, Y. Ikeda, and H. Miyazaki, “Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model,” Journal of Thrombosis and Haemostasis, vol. 3, no. 2, pp. 355–360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., “The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina,” The New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. L. M. Biasucci, G. Liuzzo, G. Fantuzzi et al., “Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events,” Circulation, vol. 99, no. 16, pp. 2079–2084, 1999. View at Google Scholar · View at Scopus
  49. J. Danesh, J. G. Wheeler, G. M. Hirschfield et al., “C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1387–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. E. R. Ferreiró, C. P. Boissonnet, R. Pizarro et al., “Independent prognostic value of elevated C-reactive protein in unstable angina,” Circulation, vol. 100, no. 19, pp. 1958–1963, 1999. View at Google Scholar · View at Scopus
  51. L. M. Biasucci, G. Liuzzo, R. L. Grillo et al., “Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability,” Circulation, vol. 99, no. 7, pp. 855–860, 1999. View at Google Scholar · View at Scopus
  52. C. C. Folman, G. E. Linthorst, J. Van Mourik et al., “Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis?” Thrombosis and Haemostasis, vol. 83, no. 6, pp. 923–930, 2000. View at Google Scholar · View at Scopus
  53. R. Sungaran, B. Markovic, and B. H. Chong, “Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization,” Blood, vol. 89, no. 1, pp. 101–107, 1997. View at Google Scholar · View at Scopus
  54. R. Sungaran, O. T. Chisholm, B. Markovic, L. M. Khachigian, Y. Tanaka, and B. H. Chong, “The role of platelet α-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells,” Blood, vol. 95, no. 10, pp. 3094–3101, 2000. View at Google Scholar · View at Scopus
  55. L. A. Harker, U. M. Marzec, P. Hunt et al., “Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates,” Blood, vol. 88, no. 2, pp. 511–521, 1996. View at Google Scholar · View at Scopus
  56. L. Erhardt, “Cigarette smoking: an undertreated risk factor for cardiovascular disease,” Atherosclerosis, vol. 205, no. 1, pp. 23–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. G. A. FitzGerald, J. A. Oates, and J. Nowak, “Cigarette smoking and hemostatic function,” American Heart Journal, vol. 115, no. 1, pp. 267–271, 1988. View at Google Scholar · View at Scopus
  58. Y. Takajo, H. Ikeda, N. Haramaki, T. Murohara, and T. Imaizumi, “Augmented oxidative stress of platelets in chronic smokers: mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability,” Journal of the American College of Cardiology, vol. 38, no. 5, pp. 1320–1327, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Heeschen, J. J. Jang, M. Weis et al., “Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis,” Nature Medicine, vol. 7, no. 7, pp. 833–839, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. R. P. Tracy, B. M. Psaty, E. Macy et al., “Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 10, pp. 2167–2176, 1997. View at Google Scholar · View at Scopus
  62. M. A. Mendall, P. Patel, M. Asante et al., “Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease,” Heart, vol. 78, no. 3, pp. 273–277, 1997. View at Google Scholar · View at Scopus
  63. S. A. Harding, J. Sarma, D. H. Josephs et al., “Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers,” Circulation, vol. 109, no. 16, pp. 1926–1929, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Lupia, O. Bosco, A. Goffi et al., “Thrombopoietin contributes to enhanced platelet activation in cigarette smokers,” Atherosclerosis, vol. 210, no. 1, pp. 314–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. B. A. Fiedel and H. Gewurz, “Effects of C reactive protein on platelet function. I. Inhibition of platelet aggregation and release reactions,” Journal of Immunology, vol. 116, no. 5, pp. 1289–1294, 1976. View at Google Scholar · View at Scopus
  66. D. Blache, “Involvement of hydrogen and lipid peroxides in acute tobacco smoking- induced platelet hyperactivity,” American Journal of Physiology, vol. 268, no. 2, pp. H679–H685, 1995. View at Google Scholar · View at Scopus
  67. E. M. Wolber and W. Jelkmann, “Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B,” Journal of Interferon and Cytokine Research, vol. 20, no. 5, pp. 499–506, 2000. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Ishiguro, Y. Suzuki, M. Mito et al., “Elevation of serum thrombopoietin precedes thrombocytosis in acute infections,” British Journal of Haematology, vol. 116, no. 3, pp. 612–618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Bjerre, R. Ovstebo, P. Kierulf, S. Halvorsen, and P. Brandtzaeg, “Fulminant meningococcal septicemia: dissociation between plasma thrombopoietin levels and platelet counts,” Clinical Infectious Diseases, vol. 30, no. 4, pp. 643–647, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Reinhold, J. Zhang, R. Geßner, U. Felderhoff-Mueser, M. Obladen, and C. Dame, “High thrombopoietin concentrations in the cerebrospinal fluid of neonates with sepsis and intraventricular hemorrhage may contribute to brain damage,” Journal of Interferon and Cytokine Research, vol. 27, no. 2, pp. 137–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Oygür, M. Tunga, Y. Mumcu et al., “Thrombopoietin levels of thrombocytopenic term and preterm newborns with infection,” American Journal of Perinatology, vol. 18, no. 5, pp. 279–285, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Lupia, O. Bosco, F. Mariano et al., “Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation,” Journal of Thrombosis and Haemostasis, vol. 7, no. 6, pp. 1000–1008, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. D. J. Kuter, “The physiology of platelet production,” Stem Cells, vol. 14, no. 1, supplement, pp. 88–101, 1996. View at Google Scholar · View at Scopus
  74. K. Kaushansky, “Thrombopoietin: a tool for understanding thrombopoiesis,” Journal of Thrombosis and Haemostasis, vol. 1, no. 7, pp. 1587–1592, 2003. View at Google Scholar · View at Scopus
  75. D. J. Kuter and C. G. Begley, “Recombinant human thrombopoietin: basic biology and evaluation of clinical studies,” Blood, vol. 100, no. 10, pp. 3457–3469, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Kumar, C. Haery, and J. E. Parrillo, “Myocardial dysfunction in septic shock: part I. Clinical manifestation of cardiovascular dysfunction,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 15, no. 3, pp. 364–376, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. M. W. Merx and C. Weber, “Sepsis and the heart,” Circulation, vol. 116, no. 7, pp. 793–802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Rudiger and M. Singer, “Mechanisms of sepsis-induced cardiac dysfunction,” Critical Care Medicine, vol. 35, no. 6, pp. 1599–1608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Kumar, A. Krieger, S. Symeoneides, A. Kumar, and J. E. Parrillo, “Myocardial dysfunction in septic shock: part II. Role of cytokines and nitric oxide,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 15, no. 4, pp. 485–511, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. J. E. Parrillo, C. Burch, J. H. Shelhamer, M. M. Parker, C. Natanson, and W. Schuette, “A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance,” Journal of Clinical Investigation, vol. 76, no. 4, pp. 1539–1553, 1985. View at Google Scholar
  81. T. Gulick, M. K. Chung, S. J. Pieper, L. G. Lange, and G. F. Schreiner, “Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 17, pp. 6753–6757, 1989. View at Google Scholar · View at Scopus
  82. A. Kumar, V. Thota, L. Dee, J. Olson, E. Uretz, and J. E. Parrillo, “Tumor necrosis factor α and interleukin 1β are responsible for in vitro myocardial cell depression induced by human septic shock serum,” Journal of Experimental Medicine, vol. 183, no. 3, pp. 949–958, 1996. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Kumar, R. Brar, P. Wang et al., “Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility,” American Journal of Physiology, vol. 276, no. 1, pp. R265–R276, 1999. View at Google Scholar · View at Scopus
  84. A. Kumar, B. Paladugu, J. Mensing, A. Kumar, and J. E. Parrillo, “Nitric oxide-dependent and -independent mechanisms are involved in TNF-α-induced depression of cardiac myocyte contractility,” American Journal of Physiology, vol. 292, no. 5, pp. R1900–R1906, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Lupia, T. Spatola, A. Cuccurullo et al., “Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum,” Basic Research in Cardiology, vol. 105, no. 5, pp. 609–620, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. F. Brizzi, E. Battaglia, A. Rosso et al., “Regulation of polymorphonuclear cell activation by thrombopoietin,” Journal of Clinical Investigation, vol. 99, no. 7, pp. 1576–1584, 1997. View at Google Scholar · View at Scopus
  87. L. T. Archer, M. R. Black, and L. B. Hinshaw, “Myocardial failure with altered response to adrenaline shock,” British Journal of Pharmacology, vol. 54, no. 2, pp. 145–155, 1975. View at Google Scholar · View at Scopus
  88. H. J. Silverman, N. H. Lee, and E. E. El-Fakahany, “Effects of canine endotoxin shock on lymphocytic beta-adrenergic receptors,” Circulatory Shock, vol. 32, no. 4, pp. 293–306, 1990. View at Google Scholar · View at Scopus
  89. G. Bernardin, A. D. Strosberg, A. Bernard, M. Mattei, and S. Marullo, “β-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans,” Intensive Care Medicine, vol. 24, no. 12, pp. 1315–1322, 1998. View at Publisher · View at Google Scholar · View at Scopus
  90. H. J. Silverman, R. Penaranda, J. B. Orens, and N. H. Lee, “Impaired β-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines,” Critical Care Medicine, vol. 21, no. 1, pp. 31–39, 1993. View at Google Scholar · View at Scopus
  91. J. Hescheler, R. Meyer, S. Plant, D. Krautwurst, W. Rosenthal, and G. Schultz, “Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart,” Circulation Research, vol. 69, no. 6, pp. 1476–1486, 1991. View at Google Scholar · View at Scopus
  92. H. Post, R. Schulz, P. Gres, and G. Heusch, “No involvement of nitric oxide in the limitation of β-adrenergic inotropic responsiveness during ischemia,” American Journal of Physiology, vol. 281, no. 6, pp. H2392–H2397, 2001. View at Google Scholar · View at Scopus
  93. R. Schulz, M. Kelm, and G. Heusch, “Nitric oxide in myocardial ischemia/reperfusion injury,” Cardiovascular Research, vol. 61, no. 3, pp. 402–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Dörge, R. Schulz, S. Belosjorow et al., “Coronary microembolization: the role of TNF-α in contractile dysfunction,” Journal of Molecular and Cellular Cardiology, vol. 34, no. 1, pp. 51–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Thielmann, H. Dörge, C. Martin et al., “Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-α, and sphingosine,” Circulation Research, vol. 90, no. 7, pp. 807–813, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. M. F. Brizzi, E. Battaglia, G. Montrucchio et al., “Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism,” Circulation Research, vol. 84, no. 7, pp. 785–796, 1999. View at Google Scholar · View at Scopus
  97. J. E. Cardier and J. Dempsey, “Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells,” Blood, vol. 91, no. 3, pp. 923–929, 1998. View at Google Scholar · View at Scopus
  98. J. E. Cardier, “Effects of megakaryocyte growth and development factor (thrombopoietin) on liver endothelial cells in vitro,” Microvascular Research, vol. 58, no. 2, pp. 108–113, 1999. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Ramella, M. P. Gallo, T. Spatola, E. Lupia, and G. Alloatti, “A novel role of thrombopoietin as a physiological modulator of coronary flow,” Regulatory Peptides, vol. 167, no. 1, pp. 5–8, 2011. View at Publisher · View at Google Scholar
  100. K. Li, R. Y. T. Sung, Z. H. Wei et al., “Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin,” Circulation, vol. 113, no. 18, pp. 2211–2220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. J. E. Baker, J. Su, A. Hsu et al., “Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats,” Cardiovascular Research, vol. 77, no. 1, pp. 44–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Y.-Y. Chan, P. Xiang, L. Zhou et al., “Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks,” European Journal of Heart Failure, vol. 13, no. 4, pp. 366–376, 2011. View at Publisher · View at Google Scholar
  103. M. Majka, J. Ratajczak, G. Villaire et al., “Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets,” Experimental Hematology, vol. 30, no. 7, pp. 751–760, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. O. E. Sigurjonsson, K. O. Gudmundsson, V. Haraldsdottir, T. Rafnar, B. A. Agnarsson, and S. Gudmundsson, “Flt3/Flk-2 ligand in combination with thrombopoietin decreases apoptosis in megakaryocyte development,” Stem Cells and Development, vol. 13, no. 2, pp. 183–191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Liu, K. Li, P. M. P. Yuen et al., “Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow,” Bone Marrow Transplantation, vol. 24, no. 3, pp. 247–252, 1999. View at Google Scholar · View at Scopus
  106. W. Chen, S. Antonenko, J. M. Sederstrom et al., “Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors,” Blood, vol. 103, no. 7, pp. 2547–2553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. X. Liu, Z. Chen, C. C. Chua et al., “Melatonin as an effective protector against doxorubicin-induced cardiotoxicity,” American Journal of Physiology, vol. 283, no. 1, pp. H254–H263, 2002. View at Google Scholar · View at Scopus
  108. S. Matoba, P. M. Hwang, T. Nguyen, and Y. Shizukuda, “Evaluation of pulsed Doppler tissue velocity imaging for assessing systolic function of murine global heart failure,” Journal of the American Society of Echocardiography, vol. 18, no. 2, pp. 148–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. E. Van Os, Y. P. Wu, J. G. Pouwels et al., “Thrombopoietin increases platelet adhesion under flow and decreases rolling,” British Journal of Haematology, vol. 121, no. 3, pp. 482–490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Schattner, R. G. Pozner, A. B. Gorostizaga, and M. A. Lazzari, “Effect of thrombopoietin and granulocyte colony-stimulating factor on platelets and polymorphonuclear leukocytes,” Thrombosis Research, vol. 99, no. 2, pp. 147–154, 2000. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Van Willigen, G. Gorter, and J. -W. N. Akkerman, “Thrombopoietin increases platelet sensitivity to α-thrombin via activation of the ERK2-cPLA2 pathway,” Thrombosis and Haemostasis, vol. 83, no. 4, pp. 610–616, 2000. View at Google Scholar
  112. A. Oda, Y. Miyakawa, B. J. Druker et al., “Thrombopoietin-induced signal transduction and potentiation of platelet activation,” Thrombosis and Haemostasis, vol. 82, no. 2, pp. 377–384, 1999. View at Google Scholar · View at Scopus
  113. Y. Ezumi, T. Uchiyama, and H. Takayama, “Thrombopoietin potentiates the protein-kinase-C-mediated activation of mitogen-activated protein kinase/ERK kinases and extracellular signal-regulated kinases in human platelets,” European Journal of Biochemistry, vol. 258, no. 3, pp. 976–985, 1998. View at Google Scholar · View at Scopus
  114. M. Fontenay-Roupie, G. Huret, J. P. Loza et al., “Thrombopoietin activates human platelets and induces tyrosine phosphorylation of p80/85 cortactin,” Thrombosis and Haemostasis, vol. 79, no. 1, pp. 195–201, 1998. View at Google Scholar · View at Scopus
  115. T. Wun, T. Paglieroni, W. P. Hammond, K. Kaushansky, and D. C. Foster, “Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro,” American Journal of Hematology, vol. 54, no. 3, pp. 225–232, 1997. View at Google Scholar
  116. Y. Kubota, T. Arai, T. Tanaka et al., “Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation,” Stem Cells, vol. 14, no. 4, pp. 439–444, 1996. View at Google Scholar · View at Scopus
  117. B. Rodriguez-Linares and S. P. Watson, “Thrombopoietin potentiates activation of human platelets in association with jak2 and tyk2 phosphorylation,” Biochemical Journal, vol. 316, no. 1, pp. 93–98, 1996. View at Google Scholar · View at Scopus
  118. C. F. Toombs, C. H. Young, J. A. Glaspy, and B. C. Varnum, “Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation,” Thrombosis Research, vol. 80, no. 1, pp. 23–33, 1995. View at Publisher · View at Google Scholar · View at Scopus
  119. A. Köhler, K. De Filippo, M. Hasenberg et al., “G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands,” Blood, vol. 117, no. 16, pp. 4349–4357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. Terada, F. Hato, C. Sakamoto et al., “Thrombopoietin stimulates ex vivo expansion of mature neutrophils in the early stages of differentiation,” Annals of Hematology, vol. 82, no. 11, pp. 671–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. M. Eguchi, H. Masuda, S. Kwon et al., “Lesion-targeted thrombopoietin potentiates vasculogenesis by enhancing motility and enlivenment of transplanted endothelial progenitor cells via activation of Akt/mTOR//p70s6kinase signaling pathway,” Journal of Molecular and Cellular Cardiology, vol. 45, no. 5, pp. 661–669, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Schmelzer, A. Deiwick, H. Bruns, H. C. Fiegel, and A. Bader, “Thrombopoietin is a growth factor for rat hepatic progenitors,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 3, pp. 209–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. O. Hoffmann, O. Rung, A. R. Im et al., “Thrombopoietin contributes to neuronal damage in experimental bacterial meningitis,” Infection and Immunity, vol. 79, no. 2, pp. 928–936, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Zhou, J. Li, D. M. Rosenbaum, and F. C. Barone, “Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury,” Journal of Cerebral Blood Flow and Metabolism, vol. 31, no. 3, pp. 924–933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Zhang, D. Freyer, O. Rung, A. R. Im, O. Hoffmann, and C. Dame, “Inflammation stimulates thrombopoietin (Tpo) expression in rat brain-derived microvascular endothelial cells, but suppresses Tpo in astrocytes and microglia,” Journal of Interferon and Cytokine Research, vol. 30, no. 7, pp. 465–469, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. A. Samoylenko, N. Byts, K. Rajalingam et al., “Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and erk signalling,” Cellular Signalling, vol. 20, no. 1, pp. 154–162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. H. Ehrenreich, M. Hasselblatt, F. Knerlich et al., “A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 862–867, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. A. V. Sirotkin, P. Sanislo, H. J. Schaeffer et al., “Thrombopoietin regulates proliferation, apoptosis, secretory activity and intracellular messengers in porcine ovarian follicular cells: involvement of protein kinase a,” Journal of Endocrinology, vol. 183, no. 3, pp. 595–604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. R. G. Romanelli, I. Petrai, G. Robino et al., “Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells,” American Journal of Physiology, vol. 290, no. 1, pp. G120–G128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  130. S. H. Lang, C. M. L. West, L. Jones et al., “In vitro effects of recombinant human megakaryocyte growth and development factor on primary human tumour colony growth,” Oncology, vol. 54, no. 2, pp. 141–145, 1997. View at Google Scholar · View at Scopus
  131. B. Bozkurt, G. Torre-Amione, M. S. Warren et al., “Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure,” Circulation, vol. 103, no. 8, pp. 1044–1047, 2001. View at Google Scholar · View at Scopus
  132. E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, and J. T. Willerson, “Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial,” Circulation, vol. 107, no. 25, pp. 3133–3140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Von Haehling, E. A. Jankowska, and S. D. Anker, “Tumour necrosis factor-α and the failing heart: pathophysiology and therapeutic implications,” Basic Research in Cardiology, vol. 99, no. 1, pp. 18–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. D. Chappell, K. Hofmann-Kiefer, M. Jacob et al., “TNF-α induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin,” Basic Research in Cardiology, vol. 104, no. 1, pp. 78–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. C. Gebhard, S. F. Stämpfli, C. E. Gebhard et al., “Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue factor and arterial thrombosis,” Basic Research in Cardiology, vol. 104, no. 3, pp. 285–294, 2009. View at Publisher · View at Google Scholar
  136. S. Li, S. Zhong, K. Zeng et al., “Blockade of NF-κB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats,” Basic Research in Cardiology, vol. 105, no. 1, pp. 139–150, 2010. View at Publisher · View at Google Scholar · View at Scopus